GSK (LON:GSK) Stock Crosses Above 200-Day Moving Average - Here's Why

GSK plc (LON:GSK - Get Free Report) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 1,413.02 ($19.00) and traded as high as GBX 1,445.50 ($19.44). GSK shares last traded at GBX 1,436.16 ($19.31), with a volume of 26,820,320 shares traded.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on GSK. JPMorgan Chase & Co. reissued an "underweight" rating on shares of GSK in a research note on Friday, March 28th. Shore Capital reiterated a "buy" rating on shares of GSK in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of GBX 1,862.50 ($25.05).

GSK Stock Performance

The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The business's fifty day simple moving average is GBX 1,428.18 and its 200-day simple moving average is GBX 1,413.02. The firm has a market capitalization of £58.28 billion, a PE ratio of 23.20, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK - Get Free Report) last posted its earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.60) earnings per share for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, equities research analysts expect that GSK plc will post 175.980975 EPS for the current year.

Insider Activity

In other GSK news, insider Emma Walmsley sold 5,473 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of GBX 1,449 ($19.49), for a total transaction of £79,303.77 ($106,648.43). Company insiders own 1.61% of the company's stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.